Neuromuscular Disorders
- Vamorolone May Be a Safer Treatment for Duchenne Muscular Dystrophy in Boys
- Rituximab Studied as Add-On Therapy for New-Onset Myasthenia Gravis
- COVID-19 mRNA Vaccines Safe in Stable Patients With Myasthenia Gravis
- FDA Approves New ALS Drug Despite Uncertain Data
- Revised Amyotrophic Lateral Sclerosis Scale Valid in Assessing Functional Status
- Occupational Exposures Tied to ALS Risk
- Eculizumab Associated With Clinical Improvement in Generalized Myasthenia Gravis
- Eteplirsen Delays Pulmonary Decline in Duchenne Muscular Dystrophy
- Pulmonary Function Decline in Pediatric Duchenne Muscular Dystrophy
- In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in Second Review
- FDA Panel Skeptical of Controversial ALS Drug Ahead of Vote
- Vamorolone Effective, Safe for Boys With Duchenne Muscular Dystrophy
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
MORE CLINICAL TOOLS
